|
Statement
| 1.Date of the shareholders' meeting resolution:2022/05/20
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
(1)Director: Jason Technology Co., Ltd.
(2)Director: Jason Technology Co., Ltd. Representative: Lin, Jung Chin
(3)Director: Lejean Biotech Co., Ltd.
(4)Director: Po Chang Investment Co., Ltd.
(5)Director: Chang, Po Chih
(6)Independent Director: Ho, Mei-Yueh
(7)Independent Director: Ho, Shih-Chinn
(8)Independent Director: LIN SHIRLEY YI-HSIEN
3.Items of competitive conduct in which the officer is
permitted to engage:
Those which are not prejudice to the interests of the Company.
4.Period of permission to engage in the competitive conduct:
During the tenure of the aforementioned Directors.
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
approval votes： 305,111,338 ； disapproval votes： 264,271 ；
invalid votes： 0 ； abstention votes/no votes： 3,282,408.
Resolved, 98.85% of total represented voting rights present were
in favor and this proposal was approved as proposed
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter "N/A" below):
Director: Jason Technology Co., Ltd. Representative: Lin, Jung Chin
7.Company name of the mainland China enterprise and the
officer's position in the enterprise:
Director, Beijing Shundu Pharmaceutical Research Institute Co., Ltd.
Director, Shanghai Bao Pharmaceutical Co., Ltd.
Director, Centergene Pharmaceuticals Co., Ltd.
8.Address of the mainland China enterprise:
(1)Beijing Shundu Pharmaceutical Research Institute Co., Ltd.：Room 026,
401, 4th floor, building 1, courtyard 15, Guanghua Road, Chaoyang District,
Beijing
(2)Shanghai Bao Pharmaceutical Co., Ltd.：50 Luoxin Road, Baoshan District,
Shanghai
(3)Centergene Pharmaceuticals Co., Ltd.：Unit 301B, C13 building, bio nano
Park,218 Xinghu street, Suzhou Industrial Park
9.Operations of the mainland China enterprise:
(1) Beijing Shundu Pharmaceutical Research Institute Co., Ltd.：
Pharmaceutical technology development and consultation
(2)Shanghai Bao Pharmaceutical Co., Ltd.：Protein drug development
(3)Centergene Pharmaceuticals Co., Ltd.：Research and development
of biopharmaceutical technology
10.Impact on the company's finance and business:No
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:No
12.Any other matters that need to be specified:None.
|
